Original Article
The lncRNA TPT1-AS1 promotes the survival of neuroendocrine prostate cancer cells by facilitating autophagy

Po-An Chen1*, Pei-Ching Chang1,2*, Wayne W Yeh1,3, Tze-Yun Hu1, Yung-Chih Hong4, Yu-Chao Wang5, William J Huang6,7, Tzu-Ping Lin6,7

1Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan; 2Cancer Progression Research Center, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan; 3Section of Infection and Immunity, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA; 4Faculty of Medicine, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan; 5Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan; 6Department of Urology, Taipei Veterans General Hospital, Taipei 11217, Taiwan; 7Department of Urology, School of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan. *Co-first authors.

Received February 2, 2024; Accepted April 21, 2024; Epub May 15, 2024; Published May 30, 2024

Abstract: The lncRNA tumor protein translationally controlled 1-antisense RNA 1 (TPT1-AS1) is known for its onco-genic role in various cancers, but its impact on the pathological progression of prostate cancer remains unclear. Our previous study demonstrated that the RE1-silencing transcription factor (REST) regulates neuroendocrine differentiation (NED) in prostate cancer (PCA) by derepressing specific long non-coding RNAs (lncRNAs), including TPT1-AS1. In this study, we revealed that TPT1-AS1 is overexpressed in LNCaP and C4-2B cells after IL-6 and enzalutamide treatment. By analyzing The Cancer Genome Atlas (TCGA) prostate adenocarcinoma dataset, we detected upregulated TPT1-AS1 expression in neuroendocrine-associated PCA but not in prostate adenocarcinoma. Single-cell RNA sequencing data further confirmed the increased TPT1-AS1 levels in neuroendocrine prostate cancer (NEPC) cells. Surprisingly, functional experiments indicated that TPT1-AS1 overexpression had no stimulatory effect on NED in LNCaP cells and that TPT1-AS1 knockdown did not inhibit IL-6-induced NED. Transcriptomic analysis revealed the essential role of TPT1-AS1 in synaptogenesis and autophagy activation in neuroendocrine differentiated PCA cells induced by IL-6 and enzalutamide treatment. TPT1-AS1 was found to regulate the expression of autophagy-related genes that maintain neuroendocrine cell survival through autophagy activation. In conclusion, our data expand the current knowledge of REST-repressed lncRNAs in NED in PCA and highlight the contribution of TPT1-AS1 to protect neuroendocrine cells from cell death rather than inducing NED. Our study suggested that TPT1-AS1 plays a cytoprotective role in NEPC cells; thus, targeting TPT1-AS1 is a potential therapeutic strategy.

Keywords: Prostate cancer, neuroendocrine prostate cancer (NEPC), long non-protein coding RNA (LncRNA)

Introduction

Persistent exposure to second-generation androgen receptor inhibitors (ARIs) leads to the development of treatment-induced neuroendocrine prostate cancer (NEPC) [1, 2], a highly aggressive subtype of castration-resistant prostate cancer (CRPC) [3]. NEPC is distinguished by an epithelial lineage switch from an androgen receptor (AR)-positive to a neuroendocrine-positive state, resulting in the acquisition of AR independence [4]. This transition makes NEPC a major contributor to the resistance of CRPC to new-generation ARIs, including enzalutamide [5, 6]. Therefore, while new-generation ARIs provide initial therapeutic advantages [7, 8], prolonged use may ultimately lead to the emergence of a more challenging-to-treat manifestation, specifically NEPC. Furthermore, neuroendocrine tumors actively secrete various signaling molecules, establishing paracrine communication within the tumor microenvironment and promoting tumor progression [9]. A comprehensive understanding
of the molecular mechanisms underlying NEPC is needed for developing new treatments for prostate cancer (PCA) to prevent the emergence of more challenging-to-treat manifestations after prolonged use of ARs.

The epithelial lineage of castration-resistant prostate adenocarcinoma that switches to a neuroendocrine lineage carcinoma has been studied by both genomic and molecular approaches [10-12]. The main characteristics involved in the epigenetic regulation of this transdifferentiation include the gain of MYCN and its stabilizing factor Aurora A kinase (AURKA) [13-15] and the loss of RE1-silencing transcription factor (REST) [16-19]. REST, also known as neuron restrictive silencing factor (NRSF), is well known for its ability to assemble repressive epigenetic complexes to silence neuronal differentiation genes in neural progenitor and non-neuronal cells [20]. The repressive role of REST in regulating the neuroendocrine transdifferentiation of PCA cells was first reported in 2014 [16, 17], demonstrating that AR interacts directly with REST, recruits it to the promoters of neuroendocrine lineage genes, and inhibits their expression. Androgen deprivation [17], interleukin-6 (IL-6) [16], and hypoxia [18, 21] have all been shown to induce REST degradation and, consequently, the activation of neuroendocrine transdifferentiation in PCA cells. Mechanistically, REST induces neuroendocrine differentiation (NED) of PCA through the derepression of proteins, such as MAOA [19] and BAF53B [22], as well as long non-coding RNAs (lncRNAs), including HOTAIR [23] and LINC01801 [24]. Notably, loss of REST induced NED in PCA cells is partly linked to the activation of autophagy [16, 18, 19, 23, 24].

Autophagy is a lysosome-mediated degradation pathway that maintains cellular homeostasis and survival by recycling unwanted cytosolic components and damaged organelles [25]. Postmitotic cells, particularly neurons, are highly dependent on autophagy due to their postmitotic nature, making them highly sensitive to toxic proteins and damaged organelles. Moreover, specialized intracellular vesicle trafficking during autophagy is required for efficient cargo recycling in neurons [26, 27]. Thus, autophagy is crucial for maintaining the health of neurons [28]. The role of autophagy in NEPC was initially elucidated by concomitant activation of NED with autophagy in response to various neuroendocrine induction signals, including androgen deprivation, hypoxia, and IL-6 [16, 18, 29]. Consistent with its commitment to control neural fate, REST has also been identified as the key repressor of neuroendocrine differentiated PCA cells induced by androgen deprivation, hypoxia, and IL-6 [16-18]. Notably, the concomitant down-regulation of REST induces NED and autophagy [16, 18]. Mechanistically, a reduction in REST may induce autophagy through the de-repression of autophagy-related genes, such as Atg5 and LC3 [16] or the mitophagy-regulating gene MAOA [19].

LncRNAs are RNA transcripts longer than 200 nucleotides [30, 31] that modulate biological functions by serving as either scaffolds to recruit transcription factors to specific genomic loci [32, 33] or decoys to sequester chromatin-binding proteins or miRNAs [34]. As members of a newly defined novel epigenetic layer for transcriptional regulation, IncRNAs are involved in cancer progression and can act as tumor suppressors and oncogenes [35]. However, their involvement in NEPC remains in its early stages of exploration. To identify REST-regulated IncRNAs that participate in NED in PCA cells, we performed a comprehensive analysis involving transcriptome and small interfering RNA (siRNA) knockdown screening under REST overexpression and knockdown conditions and revealed HOTAIR [23] and LINC01801 [24] as novel NEPC-related IncRNAs implicated in the neuroendocrine differentiation of PCA cells. These data also suggest that IncRNAs may be exploited as novel biomarkers and therapeutic targets for NEPC.

Tumor protein translationally controlled 1-antisense RNA 1 (TPT1-AS1), located at chromosome region 13q14.13 of the TPT1 gene, was initially characterized as an oncogenic [36] and a poor prognosis-related [37] IncRNA in ovarian cancer. Overexpression of TPT1-AS1 was also found to promote the progression of colorectal cancer [38, 39], pancreatic cancer [40], gastric cancer [41], esophageal squamous cell carcinomas [42], and glioblastoma [43]. Conversely, TPT1-AS1 was down-regulated in breast cancer and predicted a poor progno-
LncRNA TPT1-AS1 activates autophagy in NEPC

sis for breast cancer patients [44, 45]. Furthermore, TPT1-AS1 may have opposite effects on hepatocellular carcinoma cells [46, 47]. Most importantly, its association with PCA remains to be explored.

In this study, we aimed to investigate the role of TPT1-AS1, a REST-repressed lncRNA, in the progression of NEPC. Initially, we confirmed the up-regulation of TPT1-AS1 under neuroendocrine induction conditions and in neuroendocrine-associated PCA, suggesting its potential involvement in the development of NEPC. Surprisingly, neither overexpression nor knockdown experiments targeting TPT1-AS1 affected NED. Transcriptome analysis revealed that TPT1-AS1 activates autophagy, a crucial process known to mediate NED in PCA cells. Interestingly, autophagy activation facilitated by TPT1-AS1 appears to enhance the survival of neuroendocrine cells rather than induce NED. In conclusion, given that the activation of autophagy by TPT1-AS1 is crucial for maintaining the survival of neuroendocrine cells, targeting TPT1-AS1 could induce the death of NEPC cells, thus restoring the efficacy of androgen receptor inhibitors (ARIs).

Materials and methods

Cell culture

LNCaP and C4-2B cells were cultured in RPMI 1640 (Gibco, 31800-014) supplemented with 10% FBS (HyClone, SH30071.03), 1% penicillin/streptomycin, and 30 mg/ml L-glutamine (Sigma-Aldrich, G8540). LNCaP-TR cells were cultured as described for LNCaP cells supplemented with 5 μg/ml blasticidin S (InvivoGen, ant-bl-1). For the generation of TPT1-AS1-inducible LNCaP cell line, TPT1-AS1 cDNA (synthesized by GeneArt, Thermo Fisher Scientific) was cloned and inserted into the pLenti4-CMV/TO vector and introduced into LNCaP-TR cells through lentiviral transduction, followed by selection with 200 μg/ml zeocin (InvivoGen, ant-zn-1). LNCaP-TR-shREST [16] and LNCaP-TR-TPT1-AS1 cells were maintained as described for LNCaP-TR cells supplemented with 50 μg/ml zeocin. All cells were cultured at 37°C in a humidified incubator with 5% CO₂. For drug treatment, LNCaP and C4-2B cells were treated with 100 ng/ml IL-6 in phenol red-free RPMI 1640 (Gibco) supplemented with 10% charcoal/dextran-treated FBS (CDT; HyClone, SH30068.03) and 50 nM enzalutamide.

siRNA transfection

LNCaP and C4-2B cells were seeded in culture medium at 2×10⁵ cells/well in 6-well plates and transfected with TPT1-AS1 siRNA SMART-Pool (Dharmacon, R-188212-00) at a final concentration of 20 nM using Lipofectamine RNAiMAX (Invitrogen, 13778-150) following the manufacturer’s protocol. The sequences used for siRNA-mediated knockdown of TPT1-AS1 were 5’-GCAUAUUAGCAAGCUAUA-3’, 5’-CGCCCAAGUUAAUGUAU-3’, 5’-CUAAAAGAGCUCUCAAA-3’, and 5’-UCCAGUAAUCCCAAGCAA-3’. The control siRNA siGLO Green Transfection Indicator (Dharmacon, D-001630-01) was used as a negative control to ensure transfection efficiency.

Real-time reverse transcription and quantitative PCR (real-time RT-qPCR)

Total cell RNA was isolated by TRIzol (Invitrogen, 15596-018). To detect mRNAs and lncRNAs, cDNA was generated with a SuperScript™ III First-Strand Synthesis System Kit (Invitrogen, 18080-085) using Oligo-(dT). Both RNA extraction and cDNA synthesis were performed following the manufacturer’s procedures. Real-time qPCR analysis was carried out in 96-well plates with Bio-Rad CFX96 real-time PCR detection system. All expression levels were normalized against GAPDH. The pairs of qPCR primers used were designed with PerlPrimer (http://perlprimer.sourceforge.net/). The primer sequences are listed in Table S1.

High-throughput RNA sequencing (RNA-seq) and Gene Ontology (GO) data analysis

Total RNA was extracted from control and TPT1-AS1 knockdown LNCaP cells treated with or without 100 ng/ml IL-6 in phenol red-free RPMI 1640 (Gibco, 31800022) supplemented with 10% charcoal/dextran-treated FBS (CDT; HyClone, SH30068.03) and from LNCaP cells treated with or without 50 nM enzalutamide. RNA-seq was performed using the Illumina NextSeq 2000 platform (Illumina, Inc., San Diego, CA, USA), and the raw reads were aligned to human reference genome GRCh38/hg38. Partek Flow (Partek, version 11.0.24.0102)
was used to calculate the abundances of the transcripts. Transcriptome information was obtained from RefSeq transcripts. To identify biological functions, the differentially expressed mRNAs were subjected to canonical pathway analysis using Ingenuity Pathway Analysis software (http://www.ingenuity.com).

**Immunoblotting**

Cells were lysed in NP-40 lysis buffer (0.5% NP-40 (Amresco, E109)), 1× PBS and 1× protease inhibitor (Roche, 04693132001) or RIPA lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1% NP-40; 1% sodium deoxycholate; 1 mM EDTA; ddH$_2$O). The protein concentrations were measured using Bio-Rad protein assay dye reagent (Bio-Rad, 500-0006) according to the manufacturer's protocol. Protein samples were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 0.2 μm pore size PVDF membranes by Trans-Blot Turbo RTA Transfer System (Bio-Rad, 704272), blocked with 5% BSA in 1× TBST or 5% skim milk in 1× TBST, immunobotted with primary antibodies against each of the indicated proteins, incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies, visualized with Pierce ECL Western Blotting Substrate (Thermo Scientific, 34080) and imaged using a Luminescence/Fluorescence Imaging System (FUJIFILM, LAS-4000). The primary antibodies used were anti-REST (Millipore, 07-579), anti-AR (Millipore, 06-680), anti-TUBIII (Sigma Aldrich, T2200), anti-CHGA (Thermo Fisher Scientific, MA5-13096), anti-NSE (Cell Signaling, 9536), anti-SYP (GeneTex, GTX100-865), anti-LC3 (Cell Signaling, 2775S), and anti-GAPDH (GTX100118).

**Cell proliferation assay**

LNCaP and C4-2B cells were seeded in 96-well plates, transfected with either siRNA targeting TPT1-AS1 (siTPT1-AS1) or siGLO for 48 hours, and then treated with 100 ng/mL IL-6 in phenol red-free RPMI-1640 supplemented with 10% CDT or 50 nM enzalutamide for 72 hours. After treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed according to the manufacturer's instructions. The absorbance (570 and 660 nm) was measured using a TECAN 200Pro (Tecan, Germany) multimode microplate reader. The same volume of medium was used as a blank control.

**Neurite outgrowth assay**

LNCaP cells were seeded on coverslips in 6 well plates at a density of 1×10$^5$ cell/well. Following the indicated treatments, the cells were washed twice with PBS, fixed with 4% paraformaldehyde/PBS for 20 minutes at room temperature, washed twice with PBS, and stained with Cell Membrane Stain (Invitrogen, A15001) according to the manufacturer's instructions. Finally, the coverslips were stained with Hoechst 33342 (Invitrogen, H35770) for 5 minutes at room temperature, mounted in mounting solution (Dako, S30-23), visualized/photographed by fluorescence microscopy (Lecia, DM4000B), and analyzed using MetaMorph (Molecular Devices, Neurite Outgrowth).

**miRNA target prediction**

DIANA-TarBase-v9.0 (https://dianalab.e-ce.uth.gr/tarbasev9) was used to predict the miRNAs that interacted with mRNAs.

**The Cancer Genome Atlas (TCGA) database**

RNA-seq profiles of clinical data from 33 different cancers were downloaded from TCGA. TPT1-AS1 expression was analyzed in 23 cancer tissues that contained corresponding normal tissues using two-tailed Student's t-test.

**Single-cell data processing and cell-type annotation**

The raw sequencing data were processed using the Cell Ranger (10× Genomics, version 3.1.0) analysis pipeline, followed by alignment to the human reference genome (GRCh38). The high-quality cells included were adapted from the original article for further analysis using Partek Flow (Partek, version 11.0.24.0102). Gene counts were normalized by log2(CPM+1), and genes that were not expressed in more than 99.9% of cells were excluded. Cells were clustered by graph-based clustering and visualized by t-distributed stochastic neighbor embedding (t-SNE). Luminal cells were identified based on the expression of EPCAM and keratin 8 (KRT8). Biomarker genes were identified using the compute biomarkers function in...
LncRNA TPT1-AS1 activates autophagy in NEPC

Partek Flow, and genes with a fold change ≥2 and a p-value <0.05 were selected. Biomarker genes were subjected to GO analysis using ingenuity pathway analysis (IPA) software (QIAGEN).

Statistical analysis

Statistical analysis was performed using Student’s-t test. The data are indicated as *P<0.05; **P<0.01; ***P<0.001. Statistically nonsignificant data are not shown.

Results

TPT1-AS1 increases in prostate adenocarcinoma cells undergoing neuroendocrine differentiation (NED)

To identify NEPC-associated lncRNAs, we combined REST knockdown transcriptomic analysis with siRNA screening and identified 14 potential lncRNAs, including TPT1-AS1 [24]. The RNA-seq data revealed that TPT1-AS1 expression increased following REST knockdown for 3 and 6 days (Figure 1A, left panel) [18], and this increase was validated by RT-qPCR (Figure 1A, right panel). Subsequently, we analyzed the expression of TPT1-AS1 under NED induction conditions, which coincided with a reduction in REST levels, including treatment with IL-6 and the androgen receptor antagonist enzalutamide (Figure 1B and 1C, left panel). RNA-seq data demonstrated that TPT1-AS1 was up-regulated after IL-6 treatment for 24 to 48 hours but not after 12 hours (Figure 1D). The increase in TPT1-AS1 expression following IL-6 and enzalutamide treatment for 72 hours was further confirmed by RT-qPCR analysis (Figure 1B and 1C, right panel).

To investigate whether TPT1-AS1 is a direct target of REST, we examined the promoter region of TPT1-AS1 (transcription start site (TSS) to ±1,000 bp) for possible REST binding sites (RE-1) using JASPAR (http://jaspar.genereg.net/). Unexpectedly, no RE-1 sites were identified within this region. However, it is plausible that REST might bind to genomic sequences through non-canonical RE-1 sites. Thus, we checked our ChIP-seq data published in 2018 to identify potential REST-binding sites [23]. Unfortunately, the data consistently revealed no evidence of REST binding to the TPT1-AS1 promoter. Thus, up-regulation of TPT1-AS1 in NEPC cells may be independent of direct REST repression, suggesting potential alternative regulatory mechanisms that warrant future study.

Expression profiles of TPT1-AS1 in human cancers

TPT1-AS1 has been found to be dysregulated in various cancers, and its expression is associated with patient prognosis. Notably, elevated TPT1-AS1 expression has been linked to poor prognosis in ovarian cancer [37], colorectal cancer [38, 39], pancreatic cancer [40], gastric cancer [41], and hepatocellular carcinoma [47]. Conversely, lower expression of TPT1-AS1 has been correlated with unfavorable outcomes in patients with breast cancer [44, 45]. To summarize the dysregulation of TPT1-AS1 in cancers, we analyzed the expression of TPT1-AS1 in clinical samples from the TCGA database. We discovered significant increases in TPT1-AS1 expression in colon adenocarcinoma (COAD), cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), and renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ) (Figure 2A). Conversely, TPT1-AS1 exhibited decreased expression in breast cancer (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney chromophobe (KICH), and uterine corpus endometrial carcinoma (UCEC) (Figure 2B), while no significant difference was detected in bladder urothelial carcinoma (BLCA), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), or thymoma (THYM) (Figure 2C). The results of the TCGA analysis were generally consistent with those of previous reports, except for those of ESCA, PAAD, GBM, and STAD, which did not increase. These discrepancies are probably due to the limited number of normal samples in these TCGA datasets, except for the STAD dataset. The prognostic value of TPT1-AS1 in cancers with TPT1-AS1 overexpression (Figure 2A) or underexpression (Figure 2B) was further assessed. The top 20%
LncRNA TPT1-AS1 activates autophagy in NEPC

Figure 1. TPT1-AS1 is upregulated in REST knockdown, IL-6-induced and enzalutamide-induced neuroendocrine differentiated LNCaP cells. (A) RNA sequencing (RNA-seq) and RT-qPCR data of LNCaP-TR-shREST cells treated with 1 µg/ml doxycycline (Dox). For RNA-seq, cells were treated for 0, 3, and 6 days (left panel). For RT-qPCR, cells were treated for 0 and 3 days (right panel). (B, C) Immunoblots of REST, AR, and NED markers in LNCaP cells treated with 100 ng/ml IL-6 in phenol red-free RPMI-1640 with 10% CDT (B) and with 50 nM enzalutamide (Enza) (C) for 72 hours (left panel). TPT1-AS1 expression was measured by RT-qPCR (right panel). The cells without treatment were used as the control (Ctrl). GAPDH was used as the loading control. (D) RNA-seq data of LNCaP cells treated with 100 ng/ml IL-6 in phenol red-free RPMI-1640 with 10% CDT for 12, 24, 48 hours. The transcript abundances of RNA-seq data are shown as fragments per kilobase of transcript per million mapped reads (FPKM).
Figure 2. TPT1-AS1 levels are higher in patients with PCA with high levels of neuroendocrine markers. (A-C) Comparison of TPT1-AS1 levels in tumorous and nontumorous tissues from The Cancer Genome Atlas (TCGA) dataset. TPT1-AS1 levels were significantly higher in colon adenocarcinoma (COAD), cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatic cell carcinoma (LIHC), lung adenocarcinoma (LAD), lung squamous cell carcinoma (LUSC), multiple myeloma (MM), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD), rectal adenocarcinoma (READ), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC).

D and E show disease-free survival curves for READ and UCEC, respectively, comparing TPT1-AS1 low and high expression groups. The Logrank p-values are 0.032 and 0.019, respectively.

F and G show the expression of TPT1-AS1 in CHGA and ENO2, respectively, with significant differences indicated by ** and ***. The progression-free survival curves for these groups also show significant differences with Logrank p-values of 0.0154 and 0.0423, respectively.
LncRNA TPT1-AS1 activates autophagy in NEPC

neural (KIRP), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ) tumorous tissues than in nontumorous tissues (A). TPT1-AS1 levels were significantly lower in breast cancer (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney chromophobe (KICH), and uterine corpus endometrial carcinoma (UCEC) (B). The TPT1-AS1 levels remained unchanged in bladder urothelial carcinoma (BLCA), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and thymoma (THYM) (C). (D, E) Kaplan-Meier analysis of TPT1-AS1 in READ (D) and UCEC (E) tissues. The Mantel-Cox test was used to calculate the logarithmic rank p-value (p-value in each plot). (F) TPT1-AS1 levels were compared between the tumorous samples with high (top 20%) and low (bottom 20%) expression of chromogranin A (CHGA) (left panel) and enolase-2 (ENO2) (right panel) in PRAD dataset from TCGA. (G) TCGA data were analyzed to determine the disease-free survival (top panel) and progression-free survival (bottom panel) of patients in both TPT1-AS1 and synaptophysin (SYP) high/low groups.

of the expression levels were considered high, while the bottom 20% indicated low expression. We found that TPT1-AS1 overexpression predicted poor prognosis in patients with READ (Figure 2D), while low TPT1-AS1 expression predicted poor prognosis in patients with UCEC (Figure 2E).

Unexpectedly, TPT1-AS1 did not increase in prostate adenocarcinoma (PRAD) tissue compared to normal tissue, suggesting that TPT1-AS1 may not undergo up-regulation in PRAD, but rather increase specifically in NEPC cells. To investigate this possibility, we categorized 499 PRAD samples based on the expression levels of the neuroendocrine markers chromogranin A (CHGA) and enolase-2 (ENO2), also known as neuron-specific enolase (NSE). Using the top 20% of genes with high expression and the bottom 20% with low expression, the analysis demonstrated significant up-regulation of TPT1-AS1 in the high CHGA and ENO2 groups (Figure 2F), supporting the association of TPT1-AS1 with neuroendocrine features in PRAD. To assess the prognostic value of TPT1-AS1 in NEPC, we compared patients in whom the expression levels of both TPT1-AS1 and the neuroendocrine marker synaptophysin (SYP) were high (n=20) with patients in whom both were low (n=34) in PRAD. The data indicate that TPT1-AS1 expression was a predictor of disease-free survival and progression-free survival in patients with NEPC (Figure 2G).

TPT1-AS1 expression is increased in NEPC

NEPC represents a minor population in PCA. To reveal the increase in TPT1-AS1 expression in NEPC, we downloaded four CRPC samples with an NED phenotype from GEO scRNA sequencing data (GSE137829) [48], performed unsupervised graph-based clustering (Figure 3A), and identified luminal cells using pan-epithelial marker EPCAM and its lineage marker KRT8 (Figure 3B). Next, we performed another unsupervised graph-based clustering of luminal cells (Figure 3C) and identified neuroendocrine clusters using NEURO I and NEURO II markers [12]. Ten luminal clusters were identified, where one demonstrates a high NEURO I score (Cluster 9), two exhibit high NEURO II scores (Clusters 4 and 7), and one displays a high double score (Cluster 5) (Figure 3D). As IncRNAs generally exhibit lower expression levels compared to coding RNAs, we examined the expression of TPT1-AS1 in single-cell RNA-seq data by counting cells expressing it. The findings indicated that the group with a high double neuroendocrine score had the highest percentage of cells expressing TPT1-AS1 (Figure 3E). To understand the functional characteristics of the population with high TPT1-AS1 expression, we performed Gene Ontology (GO) analysis using biomarkers specific to this cluster by Ingenuity Pathway Analysis (IPA), with a particular emphasis on nervous system signaling, given the neuronal nature of NEPC. Remarkably, our investigation also revealed the enrichment of the autophagy pathway within this cluster, providing valuable insights into the involvement of TPT1-AS1 in modulating the autophagy pathway (Figure 3F).

IL-6-induced expression of TPT1-AS1 protects neuroendocrine-differentiated LNCaP cells from cell death

To investigate the role of TPT1-AS1 in NED in PCA, we generated an inducible TPT1-AS1-overexpressing LNCaP cell line. Despite the successful induction of TPT1-AS1 confirmed by RT-qPCR (Figure 4A), the immunoblot data surprisingly revealed no increases in the levels of neuroendocrine markers (Figure 4B), suggest-
Figure 3. TPT1-AS1 expression is increased in the neuroendocrine cell population. A. T-distributed stochastic neighbor embedding (t-SNE) plot of 4 samples from GSE137829, where 17,109 single cells were grouped into 12 clusters and distinguished by different colors. The dashed line box represents the luminal cell population. B. Normalized expression of the pan-epithelial marker EPCAM and the luminal lineage marker keratin 8 (KRT8) overlaid on a tSNE plot. C. Luminal cells were combined and grouped into 10 clusters using graph-based clustering and then visualized in a t-SNE plot with distinct colors representing each luminal cluster. D. Violin plots displaying the scores of NEURO...
LncRNA TPT1-AS1 activates autophagy in NEPC

I panel (neuroendocrine genes repressed by REST) and NEURO II panel (neuroendocrine transcription factors) in luminal cell clusters. E. Percentage of prostate adenocarcinoma (Adeno), NEURO I, NEURO II, and double-positive (NEURO I and NEURO II) populations expressing TPT1-AS1. F. Ingenuity pathway analysis (IPA) was used to reveal functional categories significantly enriched in biomarker genes in the double-positive (NEURO I and NEURO II) population.
LncRNA TPT1-AS1 activates autophagy in NEPC

Figure 4. TPT1-AS1 does not affect NED but leads to cell death in neuroendocrine-differentiated LNCaP cells. (A) RT-qPCR analysis was used to assess the expression of TPT1-AS1 in LNCap-TR-TPT1-AS1 cells treated with 1 µg/ml Dox for 72 hours, with untreated cells serving as the control (Ctrl). (B) Immunoblots of neuroendocrine markers in LNCap-TR-TPT1-AS1 cells treated as described in (A). GAPDH was used as the loading control. (C) RT-qPCR was performed to detect TPT1-AS1 in LNCap cells transfected with control siGLO or siRNA targeting TPT1-AS1 (siTPT1-AS1) for 48 hours. (D) LNCap cells were transfected as described in (C) and then treated with 100 ng/mL IL-6 in phenol red-free RPMI-1640 supplemented with 10% CDT for 72 hours. Representative images (40× magnification) of LNCap cells stained with a cell membrane stain (red) and with Hoechst33342. (E) Immunoblots of REST, AR, and NED marker tubulin III (TUBIII) in LNCap cells transfected and treated as described in (D). GAPDH was used as the loading control. (F) LNCap cells were transfected as described in (C) and then treated with 100 ng/mL IL-6 in phenol red-free RPMI-1640 supplemented with 10% CDT (left panel) or with 50 nM Enza (right panel) for 72 hours. Cells were analyzed using an MTT cell viability assay.

Consequently, we hypothesized that TPT1-AS1 might specifically contribute to IL-6-induced NED. To explore this possibility, we employed an siRNA approach to knock down TPT1-AS1 in LNCap cells (Figure 4D), followed by IL-6 treatment. In line with our screening results [24], TPT1-AS1 knockdown impeded IL-6-induced neuroendocrine-like cell morphology (Figure 4D). However, the expression of neuroendocrine markers remained unchanged compared to that in IL-6-treated LNCap cells (Figure 4E). Nevertheless, we observed lower numbers of cells in the TPT1-AS1 knockdown and IL-6 treatment groups (Figure 4D), suggesting that while TPT1-AS1 overexpression did not induce NED, it may protect the survival of IL-6-induced neuroendocrine differentiated cells.

To further investigate this possibility, we conducted MTT assays on TPT1-AS1 knockdown LNCap cells under NED induction conditions, including IL-6 and enzalutamide treatments. Consistent with our hypothesis, TPT1-AS1 knockdown alone led to a slight but significant increase in cell death (Figure 4F). Notably, a considerable increase in cell death was observed in cells treated with IL-6 and enzalutamide following TPT1-AS1 knockdown (Figure 4F), highlighting the importance of TPT1-AS1 in protecting the survival of NEPC cells.

TPT1-AS1 activates autophagy in IL-6- and enzalutamide-induced NED of PCA

IL-6 concomitantly induces NED and autophagy in PCA cells [16,29]. However, the role of autophagy in the progression of NED in PCA remains unclear. Moreover, REST-repressed MAOA gene determines the destiny of neuroendocrine cells by orchestrating autophagy and apoptosis - two crucial mechanisms governing cell fate [19]. To elucidate the role of TPT1-AS1 in IL-6-induced NED, we performed RNA sequencing (RNA-seq) of LNCap cells after TPT1-AS1 knockdown and subsequent IL-6 treatment. RNA-seq analysis revealed 12,065 expressed mRNAs (FPKM>0.5), with 1,988 genes (13%) up-regulated and 1,270 genes (8%) down-regulated after IL-6 treatment. In IL-6-treated TPT1-AS1 knockdown LNCap cells, 519 genes (4%) were up-regulated, and 1,527 genes (11%) were down-regulated. Then, we performed GO analysis using IPA to identify enriched pathways, with a specific focus on pathways exhibiting opposite regulatory effect between IL-6-treated cells and IL-6-treated TPT1-AS1 knockdown cells. This approach allowed us to elucidate the pathways affected by TPT1-AS1 in response to IL-6 treatment. The positive activation of cytokine signaling, including IL-6 signaling; nervous system signaling, such as synaptogenesis signaling; and cancer-related pathways provides insights into the involvement of TPT1-AS1 in the context of IL-6-induced NED.

To validate whether TPT1-AS1 also induces autophagy in the context of enzalutamide-induced NED of PCA, we performed additional RNA-seq analysis in LNCap cells following TPT1-AS1 knockdown and subsequent enzalutamide treatment. RNA-seq revealed 12,166 expressed mRNAs (FPKM>0.5), with 2,229 upregulated genes (18%) and 1,177 down-regulated genes (9%) after enzalutamide treatment. In enzalutamide-treated TPT1-AS1 knockdown LNCap cells, 511 genes (4%) were up-regulated and 1,763 genes (14%) were down-regulated. Subsequently, we performed
LncRNA TPT1-AS1 activates autophagy in NEPC

Table 1. GO categories of TPT1-AS1-regulated genes upon IL-6 and enzalutamide treatment

<table>
<thead>
<tr>
<th>Canonical Pathway</th>
<th>LNCaP IL-6 siCtrl</th>
<th>SITPT1-AS1</th>
<th>LNCaP Enza siCtrl</th>
<th>SITPT1-AS1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytokine Signaling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dendritic Cell Maturation</td>
<td>4.23</td>
<td>-3.3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IL-15 Production</td>
<td>3.53</td>
<td>-3</td>
<td>3.41</td>
<td>-3.61</td>
</tr>
<tr>
<td>IL-6 Signaling</td>
<td>3.53</td>
<td>-2.14</td>
<td>3.55</td>
<td>-2.89</td>
</tr>
<tr>
<td>Interleukin-1 family signaling</td>
<td>2.99</td>
<td>-2.53</td>
<td>3.74</td>
<td>-2.65</td>
</tr>
<tr>
<td>Interleukin-15 signaling</td>
<td>2</td>
<td>-2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Role of JAK family kinases in IL-6-type Cytokine Signaling</td>
<td>2.68</td>
<td>-2.33</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TREM1 Signaling</td>
<td>2.53</td>
<td>-2.24</td>
<td>2.24</td>
<td>-</td>
</tr>
<tr>
<td><strong>Cellular Stress and Injury</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenomedullin signaling pathway</td>
<td>3.67</td>
<td>-2.99</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Autophagy</td>
<td>3.86</td>
<td>-2.29</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Cachexia Signaling Pathway</td>
<td>3.79</td>
<td>-2.12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ferroptosis Signaling Pathway</td>
<td>2.54</td>
<td>-3.15</td>
<td>2.75</td>
<td>-</td>
</tr>
<tr>
<td>Immunogenic Cell Death Signaling Pathway</td>
<td>2.84</td>
<td>-2.24</td>
<td>-</td>
<td>-2.24</td>
</tr>
<tr>
<td>NOD1/2 Signaling Pathway</td>
<td>2.12</td>
<td>-2.67</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pulmonary Fibrosis Idiopathic Signaling Pathway</td>
<td>3.25</td>
<td>-2.19</td>
<td>3.58</td>
<td>-2.67</td>
</tr>
<tr>
<td>S100 Family Signaling Pathway</td>
<td>3.44</td>
<td>-3.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Neurotransmitters and Other Nervous System Signaling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholecystokinin/Gastrin-mediated Signaling</td>
<td>4.04</td>
<td>-2.18</td>
<td>3.27</td>
<td>-2.5</td>
</tr>
<tr>
<td>CREB Signaling in Neurons</td>
<td>3.4</td>
<td>-3.46</td>
<td>5.37</td>
<td>-5.76</td>
</tr>
<tr>
<td>Dopamine-DARPP32 Feedback in cAMP Signaling</td>
<td>2.36</td>
<td>-2.71</td>
<td>-</td>
<td>-2.18</td>
</tr>
<tr>
<td>Endocannabinoid Neuronal Synapse Pathway</td>
<td>2.36</td>
<td>-2.11</td>
<td>2.24</td>
<td>-</td>
</tr>
<tr>
<td>GNRH Signaling</td>
<td>3.66</td>
<td>-3.44</td>
<td>3.8</td>
<td>-2.67</td>
</tr>
<tr>
<td>GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells</td>
<td>2.84</td>
<td>-2.71</td>
<td>3.84</td>
<td>-3.15</td>
</tr>
<tr>
<td>Gustation Pathway</td>
<td>2.12</td>
<td>-3.27</td>
<td>2.71</td>
<td>-2.24</td>
</tr>
<tr>
<td>Netrin Signaling</td>
<td>2.5</td>
<td>-3.15</td>
<td>2.65</td>
<td>-2.68</td>
</tr>
<tr>
<td>NGF Signaling</td>
<td>3.4</td>
<td>-2.32</td>
<td>3.3</td>
<td>-2.89</td>
</tr>
<tr>
<td>Orexin Signaling Pathway</td>
<td>3.28</td>
<td>-2.89</td>
<td>4.42</td>
<td>-3.77</td>
</tr>
<tr>
<td>SNAKE Signaling Pathway</td>
<td>2.52</td>
<td>-2.53</td>
<td>3.5</td>
<td>-2.31</td>
</tr>
<tr>
<td>Synaptogenesis Signaling Pathway</td>
<td>2.94</td>
<td>-2.61</td>
<td>3.81</td>
<td>-3.54</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cachexia Signaling Pathway</td>
<td>3.79</td>
<td>-2.12</td>
<td>-</td>
<td>-3.77</td>
</tr>
<tr>
<td>Colorectal Cancer Metastasis Signaling</td>
<td>4.73</td>
<td>-2.13</td>
<td>3.21</td>
<td>-2.86</td>
</tr>
<tr>
<td>FAK Signaling</td>
<td>4.88</td>
<td>-3.97</td>
<td>6.21</td>
<td>-5.66</td>
</tr>
<tr>
<td>Molecular Mechanisms of Cancer</td>
<td>5.4</td>
<td>-4.05</td>
<td>5.92</td>
<td>-5.46</td>
</tr>
<tr>
<td>PTEN Signaling</td>
<td>-2.5</td>
<td>2.14</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>S100 Family Signaling Pathway</td>
<td>3.44</td>
<td>-3.1</td>
<td>5.51</td>
<td>-5.46</td>
</tr>
</tbody>
</table>

GO analysis, focusing on pathways associated with IL-6 treatment, including pathways involved in cytokine signaling, nervous system signaling, cancer, and autophagy. Although not all IL-6 treatment-enriched pathways were activated by enzalutamide, similar results were observed. Most importantly, knockdown of TPT1-AS1 via siRNA abolished the increase in autophagy pathway enriched by enzalutamide treatment (Table 1). These findings collectively suggest that TPT1-AS1 plays a role in activating autophagy during NED.

TPT1-AS1 is required for autophagy activation by IL-6 and enzalutamide

To elucidate whether TPT1-AS1 is indeed required for IL-6- and enzalutamide-induced
LncRNA TPT1-AS1 activates autophagy in NEPC

Autophagy activation, we used siRNA to knock down TPT1-AS1 in LNCaP cells. TPT1-AS1 knockdown attenuated IL-6-induced autophagy, as evidenced by decreased levels of LC3-II (Figure 5A), in LNCaP cells. Similarly, TPT1-AS1 knockdown reduced the autophagy induced by enzalutamide treatment (Figure 5B). These findings are consistent with previous reports showing that autophagy is activated in neuroendocrine cells induced by IL-6 [16, 29] and enzalutamide [49].

Given that IPA analysis revealed an association between TPT1-AS1 and autophagy, the expression levels of 12 genes involved in the autophagy pathway were assessed using RT-qPCR. The results demonstrated that IL-6 treatment increased the expression of ATG2A, MAPK10, PPM1J, RB1CC1, TGFA, VPS41, and WIPI1 (Figure 5C). Subsequently, TPT1-AS1 knockdown significantly attenuated IL-6-induced expression of MAPK10, PPM1J, and RB1CC1 (Figure 5C). To further investigate whether MAPK10, PPM1J, and RB1CC1 are also activated by enzalutamide and whether TPT1-AS1 is essential for their activation under enzalutamide treatment conditions, similar experiments were performed. The results showed that enzalutamide treatment activated MAPK10, PPM1J, and RB1CC1, and TPT1-AS1 knockdown abolished this activation (Figure 5D). Notably, the impact of TPT1-AS1 on the activation of these autophagy-related genes was more pronounced in the context of enzalutamide treatment. Collectively, these findings further support the notion that TPT1-AS1 is involved in autophagy activation by up-regulating the expression of autophagy-related genes.
Validation of TPT1-AS1 upregulation and its cytoprotective role in neuroendocrine differentiated C4-2B cells

In this section, we aimed to confirm the involvement/role of TPT1-AS1 in NED using C4-2B cells, a CRPC subline derived from LNCaP cells. First, we assessed whether TPT1-AS1 is upregulated under NED induction conditions, focusing on IL-6 and enzalutamide treatments (Figure 6A and 6B, left panel). Consistent with our findings in LNCAp cells (Figure 1), RT-qPCR analysis confirmed that TPT1-AS1 expression increased following both IL-6 and enzalutamide treatments in C4-2B cells (Figure 6A and 6B, right panel). Second, we used siRNA to knock-
LncRNA TPT1-AS1 activates autophagy in NEPC

down TPT1-AS1 expression in C4-2B cells (Figure 6C) and treated the cells with IL-6. Although IL-6 induced only a slight increase in the expression of neuroendocrine markers in C4-2B cells, TPT1-AS1 knockdown consistently exhibited no alteration in this neuroendocrine induction (Figure 6D). Third, we conducted MTT assays on TPT1-AS1 knockdown C4-2B cells under NED induction conditions, including IL-6 and enzalutamide treatments. In agreement with our observations in LNCaP cells (Figure 4F), TPT1-AS1 knockdown resulted in a slight increase in cell death (Figure 6E and 6F), while a considerable increase in cell death was noted in cells treated with IL-6 and enzalutamide following TPT1-AS1 knockdown (Figure 6E and 6F), highlighting the importance of TPT1-AS1 in protecting the survival of NEPC cells differentiated from CRPC cells. Finally, we validated whether TPT1-AS1 is indispensable for the activation of IL-6- and enzalutamide-induced autophagy in C4-2B cells. To test this possibility, we knocked down TPT1-AS1 in C4-2B cells, followed by treatment with IL-6 and enzalutamide. Consistently, TPT1-AS1 attenuated autophagy induced by IL-6 and enzalutamide treatment (Figure 6G).

Discussion

NEPC, which was once an infrequent phenomenon, has become increasingly prevalent due to the widespread use of new-generation ARIs. Furthermore, pathogenic conditions, such as hypoxia [18] and elevated serum levels of IL-6 in patients with CRPC and metastatic PCA after androgen-deprivation therapy [50-52], have also been identified as inducers of NED in PCA cells [16, 18, 29]. Given the lethality of NEPC and the current lack of effective treatment options, extensive research has been devoted to understanding the molecular mechanisms underlying its evolution. In addition to genetic mutations and amplifications [53, 54], epigenetic regulation of chromatin accessibility for transcription has become another pivotal factor in NEPC [55]. More importantly, unlike irreversible genetic events with limited targeted therapy options, the role of epigenetics in driving disease progression holds particular interest, as its potential reversibility and susceptibility to target by epigenetic enzymes.

REST serves as a master epigenetic repressor that governs the expression of NED driver genes in PCA [16-18]. Down-regulation of REST, a transcriptional repressor known to regulate neuronal differentiation [56] and tumor growth [57], has been observed in up to 50% of clinical NEPC specimens [58]. However, the mechanisms underlying the role of REST in regulating NED in PCA remain to be elucidated. To address this issue, we performed a bioinformatic analysis of transcriptomic data and revealed that, in addition to targeting neuronal-related genes, REST also regulates autophagy-related genes [16] and the mitochondrial outer membrane-bound enzyme MAOA. MAOA participates in inhibiting apoptosis and activating autophagy [19]. These data suggest that autophagy is activated simultaneously with NED in PCA.

Importantly, the epigenetic/non-coding interactome is emerging as a novel mechanism orchestrating the initiation and progression of NEPC [59]. Given the relatively high tissue specificity of IncRNAs, exploring NEPC-associated IncRNAs holds promise for identifying specific diagnostic, prognostic, and therapeutic targets for NEPC. One promising example is the FDA-approved IncRNA biomarker, prostate cancer gene 3 (PCA3), which is now routinely used to diagnose PCA [60, 61]. Therefore, we hypothesized that REST might also play a pivotal role in the negative regulation of IncRNAs with NED-driving potential. The down-regulation of REST during NED may concomitantly up-regulate the expression of those IncRNAs and consequently induce NED. To identify IncRNAs as potential drivers of NED, we reannotated our transcriptome data using the non-coding RNA database, NONCODEv4 [62], and identified IncRNAs that are up-regulated after REST knockdown and concurrent NED. Using the siRNA knockdown approach, we validated HOTAIR [23] and LINCO1801 [24] as novel neuroendocrine-associated IncRNAs. Notably, overexpression of both HOTAIR and LINCO1801 not only induces NED in PCA cells but also regulates genes enriched in the autophagy pathway [23, 24]. Collectively, our study highlighted that REST may concomitantly induce NED and autophagy by derepressing both coding and noncoding RNAs.

Our previous study involving REST knockdown transcriptomic analysis combined with siRNA screening also identified TPT1-AS1 as another potential REST-repressed neuroendocrine-associated IncRNA [24]. TPT1-AS1 has been
LncRNA TPT1-AS1 activates autophagy in NEPC

LncRNA TPT1-AS1 activates autophagy in NEPC

studied extensively and is recognized as a tumor-associated lncRNA with varying expression levels in different types of cancer [38-47, 63]. To comprehensively assess its expression in various cancers, we analyzed TPT1-AS1 levels in clinical samples from the TCGA database. Among the 33 cancers analyzed, only 23 had corresponding normal tissue data. The analysis revealed that TPT1-AS1 is overexpressed in cholangiocarcinoma and colorectal, liver, and head and neck cancers (Figure 2A), while it is down-regulated in breast, cervical, and endometrial cancers (Figure 2B). Interestingly, among the three types of kidney cancer, TPT1-AS1 exhibited variable expression and was overexpressed in KIRC and KIRP but down-regulated in KICH (Figure 2A and 2B). Furthermore, our TCGA data indicated that TPT1-AS1 levels in PCA were similar between normal and cancerous tissues (Figure 2C). However, when we subgrouped them by neuroendocrine markers, we observed an overexpression of TPT1-AS1 in NEPC (Figure 2D). These findings support the necessity of separately elucidating the tumorigenic role of TPT1-AS1 in different types and subtypes of cancer. More interestingly, lncRNAs, particularly TPT1-AS1, have been recognized to regulate transcription by acting as competitive endogenous RNAs (ceRNAs) that sponge miRNAs [34]. Notably, in breast cancer, TPT1-AS1 has been identified as a sponge for miR-3156-5p and miR-330-3p, resulting in up-regulation of CASP2 and QKI, respectively [44, 45]. In glioma, TPT1-AS1 promotes cell proliferation by sponging miR-23a-5p and miR-770-5p, leading to the up-regulation of ECM1 and STMM1, respectively [43, 64]. In pancreatic cancer, TPT1-AS1 acts as a sponge for miR-30a-5p, contributing to the up-regulation of ITGB3 [40]. Similarly, in esophageal cancer, TPT1-AS1 functions as a sponge for miR-26a, resulting in the up-regulation of HMGA1 [42]. These findings suggest that TPT1-AS1 modulates gene expression by interacting with multiple miRNAs.

Given that lncRNAs modulate gene transcription by sponging miRNAs, their expression can lead to couple- and codown-regulation of target genes. This phenomenon may hold true in PCA cells treated with IL-6 and enzalutamide, as the sequence results showed that under IL-6 treatment conditions, more genes were up-regulated (1,988; 13%) than down-regulated (1,270; 8%). Notably, TPT1-AS1 knockdown under IL-6 treatment conditions significantly increased the number of down-regulated genes (1,527; 11%) compared to up-regulated genes (519; 4%). Similarly, in enzalutamide treatment groups, more genes were up-regulated (2,229; 18%) than down-regulated (1,177; 9%). Once again, TPT1-AS1 knockdown under enzalutamide treatment conditions led to a notable increase in down-regulated genes (1,763; 14%) compared to up-regulated genes (511; 4%). These observations imply a potential interplay between TPT1-AS1 and miRNAs in the context of IL-6 and enzalutamide treatments in PCA cells.

Moreover, in our study, IL-6 and enzalutamide treatment increased the expression levels of autophagy-related genes MAPK10, PPM1J, and RB1CC1, while TPT1-AS1 knockdown attenuated their expression (Figure 5C and 5D). To explore whether MAPK10, PPM1J, and RB1CC1 are potential targets of TPT1-AS1-associated miRNAs, we performed miRNA prediction using TarBase-v9.0 [65]. The prediction results showed that hsa-miR-30a-5p and hsa-miR-26a-5p could target all three identified autophagy-related genes. Additionally, RB1CC1 was also predicted to be targeted by hsa-miR-330-3p. Collectively, these data indicate a potential regulatory axis involving TPT1-AS1, miRNAs, and autophagy-related genes in the context of IL-6 and enzalutamide treatments in PCA cells. Further exploration of these interactions may provide valuable insights into the molecular mechanisms underlying PCA progression.

In this study, our focus was to elucidate the role of TPT1-AS1, a REST-repressed lncRNA, in the NED of PCA. Surprisingly, while the overexpression of TPT1-AS1 was evident in NEPC cells (Figure 1) and neuroendocrine-associated PCA (Figure 2D), no NED induction was observed after overexpression of TPT1-AS1 (Figure 4A and 4B). Moreover, TPT1-AS1 knockdown did not abolish IL-6-induced NED in LNCaP cells (Figure 4C-E). However, a notable increase in cell death was observed in LNCaP cells after TPT1-AS1 knockdown, particularly in IL-6-treated cells. This led us to hypothesize that TPT1-AS1 may not directly contribute to NED in PCA cells; instead, its upregulation might activate a cell protective mechanism preventing neuroendocrine cell death under
LncRNA TPT1-AS1 activates autophagy in NEPC

neuroendocrine induction conditions. Indeed, survival assays demonstrated that TPT1-AS1 knockdown alone caused slight cell death, while a significant increase in cell death was observed in TPT1-AS1 knockdown cells treated with IL-6 or enzalutamide (Figure 4F). Taken together, our findings suggest that using an siRNA-mediated knockdown approach to identify neuroendocrine-associated IncRNAs can reveal IncRNAs involved in maintaining cell survival rather than promoting NED in PCA cells. The knockdown of these IncRNAs resulted in neuroendocrine cell death and the absence of NED characteristics. This observation aligns with studies that have questioned the role of HOTAIR as a driver of NED in PCA [66]. Most importantly, the induction of TPT1-AS1 in triple-negative breast cancer in response to DNA methyltransferase (DNMT) inhibition [63] suggests promising therapeutic opportunities by targeting DNA demethylation to modulate TPT1-AS1 expression.

To explore the potential mechanisms underlying the protective role of TPT1-AS1, we conducted transcriptome analysis of IL-6- and enzalutamide-treated LNCaP cells, with or without TPT1-AS1 knockdown. Consistent with previous findings, our treatment induced changes in neuronal-related pathways and the autophagy pathway (Table 1). Notably, TPT1-AS1 knockdown abolished or even inhibited IL-6- and enzalutamide-induced synaptogenesis and autophagy (Table 1). This finding was confirmed using LC3-II as an autophagy activation marker, demonstrating that TPT1-AS1 knockdown eliminated autophagy activation induced by IL-6 (Figure 5A) and enzalutamide (Figure 5B), potentially through the up-regulation of multiple autophagy-related genes (Figure 5C, 5D).

As TPT1-AS1 is a well-established ceRNA that sponges numerous miRNAs and many of these miRNAs target autophagy-related genes (Figure 5C, 5D), our data suggest that TPT1-AS1 may modulate autophagy by acting as a miRNA sponge. Further exploration is warranted to elucidate these intricate interactions.

In conclusion, we identified TPT1-AS1 as a novel REST-repressed IncRNA that is overexpressed in neuroendocrine-associated PCA. TPT1-AS1 plays crucial roles in inducing autophagy-related genes, activating autophagy, and promoting cell survival in IL-6- and enzalutamide-induced NEPC cells. These findings suggest that TPT1-AS1 is a potential prognostic biomarker for NEPC and highlight TPT1-AS1 as a promising therapeutic target for NEPC.

Acknowledgements

The authors acknowledge the technical services provided by the National Genomics Center for Clinical and Biotechnological Applications of the Cancer Progression Research Center (National Yang Ming Chiao Tung University), the National Core Facility for Biopharmaceuticals (NCFB), and the National Science and Technology Council (NSTC 112-2740-B-A49-001, NSTC 111-2740-B-A49-001). This work was supported by grants to T.P.L. (MOST 109-2314-B-075-072-MY3; NSTC 112-2314-B-A49-055-MY3; NHRI NHRI-109BCCO-MF-202014-03; and Taipei Veterans General Hospital, V112C-077, V113C-075) and grants to P.C.C. (NSTC 111-2320-B-A49-030-MY3 and 112-2314-B-A49-023-MY3; and NHRI NHRI-EX111-113-11125B), and grants from the Prof. Albert Ly-Young Shen’s Medical Education Foundation, Melissa Lee Cancer Foundation, R & D Foundation of Urological Medicine, Ministry of Education, Higher Education SPROUT Project for Cancer Progression Research Center (111W31101) and the Cancer and Immunology Research Center (112W31101 and 113W031101).

Disclosure of conflict of interest

None.

Address correspondence to: Tzu-Ping Lin, Department of Urology, Taipei Veterans General Hospital, Taipei 11217, Taiwan. Tel: +886-2-2875-7519; E-mail: tplin@vghtpe.gov.tw

References

LncRNA TPT1-AS1 activates autophagy in NEPC


Suppression of basal autophagy in neural cells
Mishima K, Saito I, Okano H and Mizushima N.


Delk NA and Farach-Carson MC. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy 2012; 8: 650-663.


Zhang L, Ye F, Zuo Z, Cao D, Peng Y, Li Z, Huang J and Duan L. Long noncoding RNA TPT1-AS1 promotes the progression and metastasis of
colorectal cancer by upregulating the TPT1-mediated FAK and JAK-STAT3 signalling pathways. Aging (Albany NY) 2021; 13: 3779-3797.


[42] Cheng W, Yang F and Ma Y. IncRNA TPT1-AS1 promotes cell migration and invasion in esophageal squamous-cell carcinomas by regulating the miR-26a/HMGA1 axis. Open Med (Wars) 2023; 18: 20220533.


LncRNA TPT1-AS1 activates autophagy in NEPC

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227: 286-297.


**Table S1.** Primer sequences for RT-qPCR used in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5’-3’)</th>
<th>Reverse primer (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPT1-AS1</td>
<td>TCCTCCAGTAAATCCCAAGC</td>
<td>GATGGGTATGGCTTTGTCAC</td>
</tr>
<tr>
<td>ATG2A</td>
<td>GAGCCTTACAGACCCAGGAG</td>
<td>GTCAGTGTATCCAGGTTGAG</td>
</tr>
<tr>
<td>EGF</td>
<td>TGATTGCCCCTGACTCTACTC</td>
<td>CCACCACGATGACCTTCTG</td>
</tr>
<tr>
<td>MAPK10</td>
<td>TTCTTCCAAAGGCTAGTG</td>
<td>TCCACTTGTTATCGAATCCC</td>
</tr>
<tr>
<td>PPM1J</td>
<td>ATGCCAACAGCAGTATACAG</td>
<td>GCCGACATCCCTTCTCAG</td>
</tr>
<tr>
<td>PPP2R2C</td>
<td>GGAGCTTCAACACATCGTGAC</td>
<td>AAGAATGACCGTTACTGAC</td>
</tr>
<tr>
<td>PPP3CB</td>
<td>CGTCAAGCTGTCGCTTTCC</td>
<td>GCCATGGATGTCACCACAC</td>
</tr>
<tr>
<td>RB1CC1</td>
<td>TGAGCTAACTGTATCGAGG</td>
<td>ATTTGATCCCGTCCAGCAC</td>
</tr>
<tr>
<td>TGFA</td>
<td>CTGTTGGCTCTGGTATG</td>
<td>CTGAGTGTGGGAAATCTG</td>
</tr>
<tr>
<td>VPS41</td>
<td>ACTTCTGTCAGGGTGTC</td>
<td>CATTGATTCTCTCTGAAAGCCT</td>
</tr>
<tr>
<td>WIPI1</td>
<td>GCTTCTCTTCAACCAGGAC</td>
<td>GGGATTCTTACTGCTCCGT</td>
</tr>
</tbody>
</table>